Literature DB >> 34059748

C1q/TNF-related protein-9 ameliorates hypoxia-induced pulmonary hypertension by regulating secretion of endothelin-1 and nitric oxide mediated by AMPK in rats.

Qiaoyan Jin1, Hui Su2, Rui Yang1, Yanzhen Tan3, Buying Li3, Wei Yi3, Qianqian Dong4, Haifeng Zhang4, Wenjuan Xing5, Xin Sun6.   

Abstract

Injury/dysfunction of the endothelium of pulmonary arteries contributes to hypoxia-induced pulmonary hypertension (HPH). We investigated whether C1q/tumor necrosis factor-related protein-9 (CTRP9), a newly identified cardiovascular agent, has protective roles in the development of HPH. HPH was induced in adult male rats by chronic hypobaric hypoxia. CTRP9 overexpression by adeno-associated virus (AAV)-CTRP9 transfection attenuated the increases in right ventricular systolic pressure, right ventricular hypertrophy index, and pulmonary arterial remodeling of rats under hypoxia. Importantly, CTRP9 overexpression improved endothelium-dependent vasodilation in pulmonary arterioles in HPH rats. CTRP9 overexpression enhanced expression of phosphorylated 5'-adenosine monophosphate-activated protein kinase (p-AMPK) and phosphorylated endothelial nitric oxide synthase (p-eNOS), and reduced phosphorylated extracellular signal-regulated protein kinase (p-ERK1/2) expression in pulmonary microvascular endothelial cells (PMVECs) of HPH rats. In cultured PMVECs, CTRP9 not only preserved the decrease of AMPK and eNOS phosphorylation level and nitric oxide (NO) production induced by hypoxia, but also blocked the increase in hypoxia-induced ERK1/2 phosphorylation level and endothelin (ET)-1 production. Furthermore, the effects of CTRP9 were interrupted by inhibitors or knockdown of AMPK. CTRP9 enhances NO production and reduces ET-1 production by regulating AMPK activation. CTRP9 could be a target for HPH.

Entities:  

Year:  2021        PMID: 34059748     DOI: 10.1038/s41598-021-90779-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  30 in total

1.  C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway.

Authors:  Qijun Zheng; Yuexing Yuan; Wei Yi; Wayne Bond Lau; Yajing Wang; Xiaoliang Wang; Yang Sun; Bernard L Lopez; Theodore A Christopher; Jonathan M Peterson; G William Wong; Shiqiang Yu; Dinghua Yi; Xin-Liang Ma
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

2.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Respir J       Date:  2015-08-29       Impact factor: 16.671

3.  Targeted activation of endothelin-1 exacerbates hypoxia-induced pulmonary hypertension.

Authors:  Muhammad Gahan Satwiko; Koji Ikeda; Kazuhiko Nakayama; Keiko Yagi; Berthold Hocher; Ken-ichi Hirata; Noriaki Emoto
Journal:  Biochem Biophys Res Commun       Date:  2015-08-12       Impact factor: 3.575

Review 4.  Exosomes--vesicular carriers for intercellular communication.

Authors:  Mikael Simons; Graça Raposo
Journal:  Curr Opin Cell Biol       Date:  2009-05-11       Impact factor: 8.382

Review 5.  Pulmonary arterial hypertension: the clinical syndrome.

Authors:  Yen-Chun Lai; Karin C Potoka; Hunter C Champion; Ana L Mora; Mark T Gladwin
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

6.  Augmentation of hypoxic pulmonary vasoconstriction in the isolated perfused rat lung by in vitro antagonists of endothelium-dependent relaxation.

Authors:  V L Brashers; M J Peach; C E Rose
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

7.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; D Saleh
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

Review 8.  C1q and tumor necrosis factor superfamily: modularity and versatility.

Authors:  Uday Kishore; Christine Gaboriaud; Patrick Waters; Annette K Shrive; Trevor J Greenhough; Kenneth B M Reid; Robert B Sim; Gerard J Arlaud
Journal:  Trends Immunol       Date:  2004-10       Impact factor: 16.687

9.  C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation.

Authors:  Yang Sun; Wei Yi; Yuexing Yuan; Wayne Bond Lau; Dinghua Yi; Xiaoliang Wang; Yajing Wang; Hui Su; Xiaoming Wang; Erhe Gao; Walter J Koch; Xin-Liang Ma
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

Review 10.  Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension.

Authors:  Marius M Hoeper; Joan Albert Barberà; Richard N Channick; Paul M Hassoun; Irene M Lang; Alessandra Manes; Fernando J Martinez; Robert Naeije; Horst Olschewski; Joanna Pepke-Zaba; Margaret M Redfield; Ivan M Robbins; Rogério Souza; Adam Torbicki; Michael McGoon
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

View more
  2 in total

Review 1.  Hypoxia signaling in human health and diseases: implications and prospects for therapeutics.

Authors:  Zhen Luo; Mingfu Tian; Ge Yang; Qiaoru Tan; Yubing Chen; Geng Li; Qiwei Zhang; Yongkui Li; Pin Wan; Jianguo Wu
Journal:  Signal Transduct Target Ther       Date:  2022-07-07

Review 2.  AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension.

Authors:  Karen Flores; Patricia Siques; Julio Brito; Silvia M Arribas
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.